{"name":"MedImmune Ventures","permalink":"medimmune-ventures","crunchbase_url":"http://www.crunchbase.com/financial-organization/medimmune-ventures","homepage_url":"http://www.medimmune.com/ventures/overview.asp","blog_url":"","blog_feed_url":"","twitter_username":"","phone_number":"(301) 398-4624","description":"Venture Capital","email_address":"medimmuneventures@medimmune.com","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"tag_list":"","alias_list":"","created_at":"Fri Apr 17 16:17:04 UTC 2009","updated_at":"Sat Jun 20 07:34:22 UTC 2009","overview":"<p>MedImmune Ventures is a wholly owned venture capital fund within the AstraZeneca/MedImmune group of companies. It was created in 2002 to leverage MedImmune&#8217;s expertise in discovering, developing and commercializing biotechnology products, as well as its financial resources, to transform new ideas in biotechnology into successful products and companies.</p>\n\n<p>MedImmune Ventures invests in early- to late-stage, public or private biotechnology companies focused on discovering and developing human therapeutics. MedImmune Ventures primarily seeks to invest in areas of strategic interest to Astra Zeneca and MedImmune, including infectious diseases, cancer, inflammatory diseases, cardiovascular and metabolic disorders, pain and central nervous system disorders, and gastrointestinal disease. We are modality agnostic, investing in biologics, small molecules, and vaccines.</p>","image":{"available_sizes":[[[150,34],"assets/images/resized/0004/9449/49449v1-max-150x150.jpg"],[[183,42],"assets/images/resized/0004/9449/49449v1-max-250x250.jpg"],[[183,42],"assets/images/resized/0004/9449/49449v1-max-450x450.jpg"]],"attribution":null},"offices":[{"description":"MedImmune Ventures","address1":"One MedImmune Way ","address2":"","zip_code":"20878","city":"Gaithersburg","state_code":"MD","country_code":"USA","latitude":39.1267569,"longitude":-77.2320712}],"relationships":[{"is_past":false,"title":"Vice President","person":{"first_name":"Franklin","last_name":"H. Top","permalink":"franklin-h-top","image":null}},{"is_past":false,"title":"Senior Managing Director","person":{"first_name":"Joseph","last_name":"Amprey","permalink":"joseph-amprey","image":null}}],"investments":[{"funding_round":{"round_code":"unattributed","source_url":"http://www.rib-x.com/news_and_events/release_2009_01_26","source_description":"Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing","raised_amount":25000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":1,"funded_day":25,"company":{"name":"Rib-X Pharmaceuticals","permalink":"rib-x-pharmaceuticals","image":{"available_sizes":[[[150,49],"assets/images/resized/0004/1688/41688v1-max-150x150.png"],[[250,82],"assets/images/resized/0004/1688/41688v1-max-250x250.png"],[[282,93],"assets/images/resized/0004/1688/41688v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://venturebeat.com/2008/03/10/life-science-briefing-monday-march-10-2008/","source_description":"BrainCells raises $30M","raised_amount":30000000,"raised_currency_code":"USD","funded_year":2008,"funded_month":3,"funded_day":null,"company":{"name":"BrainCells","permalink":"braincells","image":{"available_sizes":[[[150,61],"assets/images/resized/0004/3268/43268v1-max-150x150.png"],[[191,78],"assets/images/resized/0004/3268/43268v1-max-250x250.png"],[[191,78],"assets/images/resized/0004/3268/43268v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"d","source_url":"http://www.reuters.com/article/pressRelease/idUS118179+16-Jan-2009+BW20090116","source_description":"Hydra Biosciences Raises $22 Million in Series D Financing","raised_amount":22000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":1,"funded_day":16,"company":{"name":"Hydra Biosciences","permalink":"hydra-biosciences","image":{"available_sizes":[[[150,40],"assets/images/resized/0004/8342/48342v1-max-150x150.png"],[[250,67],"assets/images/resized/0004/8342/48342v1-max-250x250.png"],[[264,71],"assets/images/resized/0004/8342/48342v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"d","source_url":"http://onbiovc.com/vaxinnate-corp-series-d-30m/","source_description":"VaxInnate Corp., Series D $30M ","raised_amount":30000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":6,"funded_day":14,"company":{"name":"VaxInnate","permalink":"vaxinnate","image":{"available_sizes":[[[150,37],"assets/images/resized/0004/8849/48849v1-max-150x150.png"],[[178,44],"assets/images/resized/0004/8849/48849v1-max-250x250.png"],[[178,44],"assets/images/resized/0004/8849/48849v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://agtc.com/about/overview.htm","source_description":"Company Overview","raised_amount":27000000,"raised_currency_code":"USD","funded_year":2003,"funded_month":11,"funded_day":1,"company":{"name":"Applied Genetics Technologies Corporation","permalink":"applied-genetics-technologies-corporation","image":{"available_sizes":[[[133,150],"assets/images/resized/0004/8997/48997v1-max-150x150.png"],[[150,169],"assets/images/resized/0004/8997/48997v1-max-250x250.png"],[[150,169],"assets/images/resized/0004/8997/48997v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"c","source_url":"http://onbiovc.com/applied-genetic-technologies-corp-series-c-118m/","source_description":"Applied Genetic Technologies Corp.: Series C $11.8M","raised_amount":11800000,"raised_currency_code":"USD","funded_year":2009,"funded_month":6,"funded_day":9,"company":{"name":"Applied Genetics Technologies Corporation","permalink":"applied-genetics-technologies-corporation","image":{"available_sizes":[[[133,150],"assets/images/resized/0004/8997/48997v1-max-150x150.png"],[[150,169],"assets/images/resized/0004/8997/48997v1-max-250x250.png"],[[150,169],"assets/images/resized/0004/8997/48997v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"angel","source_url":"http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_23/ai_n30930200/?tag=content;col1","source_description":"Arginetix, Inc. Completes $2.3 Million Initial Financing and Technology License","raised_amount":2300000,"raised_currency_code":"USD","funded_year":2008,"funded_month":10,"funded_day":23,"company":{"name":"Arginetix","permalink":"arginetx","image":{"available_sizes":[[[150,40],"assets/images/resized/0004/9307/49307v1-max-150x150.png"],[[250,67],"assets/images/resized/0004/9307/49307v1-max-250x250.png"],[[450,122],"assets/images/resized/0004/9307/49307v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"","source_description":"Capital Funding Report","raised_amount":28000000,"raised_currency_code":"USD","funded_year":2008,"funded_month":4,"funded_day":1,"company":{"name":"LigoCyte Pharmaceuticals","permalink":"ligocyte-pharmaceuticals","image":{"available_sizes":[[[150,72],"assets/images/resized/0004/9543/49543v1-max-150x150.png"],[[249,120],"assets/images/resized/0004/9543/49543v1-max-250x250.png"],[[249,120],"assets/images/resized/0004/9543/49543v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://www.bizjournals.com/boston/stories/2009/03/16/daily8.html","source_description":"NKT Therapeutics launches with $8M","raised_amount":8000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":3,"funded_day":16,"company":{"name":"NKT Therapeutics","permalink":"nkt-therapeutics","image":{"available_sizes":[[[150,20],"assets/images/resized/0004/9825/49825v1-max-150x150.jpg"],[[250,33],"assets/images/resized/0004/9825/49825v1-max-250x250.jpg"],[[450,60],"assets/images/resized/0004/9825/49825v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://onbiovc.com/virdante-pharmaceuticals-inc-series-a-30m/","source_description":"Virdante Pharmaceuticals, Inc.: Series A $30M","raised_amount":30000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":11,"funded_day":25,"company":{"name":"Virdante Pharmaceuticals","permalink":"virdante-pharmaceuticals","image":{"available_sizes":[[[150,42],"assets/images/resized/0006/4176/64176v1-max-150x150.jpg"],[[250,71],"assets/images/resized/0006/4176/64176v1-max-250x250.jpg"],[[278,79],"assets/images/resized/0006/4176/64176v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://onbiovc.com/arginetix-inc-series-b-46m/","source_description":"Arginetix, Inc.: Series B $4.6M","raised_amount":4600000,"raised_currency_code":"USD","funded_year":2009,"funded_month":11,"funded_day":2,"company":{"name":"Arginetix","permalink":"arginetx","image":{"available_sizes":[[[150,40],"assets/images/resized/0004/9307/49307v1-max-150x150.png"],[[250,67],"assets/images/resized/0004/9307/49307v1-max-250x250.png"],[[450,122],"assets/images/resized/0004/9307/49307v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=29&aid=DJFVLS0020100113e61d0002u&r=Rss&s=DJFVLS","source_description":"VentiRx Pharma Extends Series A To $51.6M  ","raised_amount":51600000,"raised_currency_code":"USD","funded_year":2010,"funded_month":1,"funded_day":13,"company":{"name":"VentiRx Pharmaceuticals","permalink":"ventirx-pharmaceuticals","image":{"available_sizes":[[[150,60],"assets/images/resized/0007/3107/73107v1-max-150x150.png"],[[220,88],"assets/images/resized/0007/3107/73107v1-max-250x250.png"],[[220,88],"assets/images/resized/0007/3107/73107v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"c","source_url":"http://www.fiercebiotech.com/node/5164","source_description":"Sequoia Pharmaceuticals Raises $35M In Series C Financing","raised_amount":35000000,"raised_currency_code":"USD","funded_year":2007,"funded_month":1,"funded_day":9,"company":{"name":"Sequoia Pharmaceuticals","permalink":"sequoia-pharmaceuticals","image":{"available_sizes":[[[150,45],"assets/images/resized/0007/9955/79955v1-max-150x150.jpg"],[[204,62],"assets/images/resized/0007/9955/79955v1-max-250x250.jpg"],[[204,62],"assets/images/resized/0007/9955/79955v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.vlstcorp.com/files/pr/pr061606.pdf","source_description":"VLST Corporation Raises $55 Million","raised_amount":55000000,"raised_currency_code":"USD","funded_year":2006,"funded_month":6,"funded_day":16,"company":{"name":"VLST Corporation","permalink":"vlst-corporation","image":{"available_sizes":[[[150,76],"assets/images/resized/0008/4234/84234v1-max-150x150.jpg"],[[189,96],"assets/images/resized/0008/4234/84234v1-max-250x250.jpg"],[[189,96],"assets/images/resized/0008/4234/84234v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"c","source_url":"http://www.freshnews.com/news/62624/mountain-view-avidia-raises-438-million-advance-new-class-pharmaceuticals","source_description":"AVIDIA RAISES $43.8 MILLION TO ADVANCE NEW CLASS OF PHARMACEUTICALS","raised_amount":43800000,"raised_currency_code":"USD","funded_year":2006,"funded_month":5,"funded_day":9,"company":{"name":"Avidia","permalink":"avidia","image":null}}},{"funding_round":{"round_code":"c","source_url":"http://www.thefreelibrary.com/VaxInnate+Secures+$40+Million+Series+C+Financing-a0153993028","source_description":"VaxInnate Secures $40 Million Series C Financing.","raised_amount":40000000,"raised_currency_code":"USD","funded_year":2006,"funded_month":10,"funded_day":25,"company":{"name":"VaxInnate","permalink":"vaxinnate","image":{"available_sizes":[[[150,37],"assets/images/resized/0004/8849/48849v1-max-150x150.png"],[[178,44],"assets/images/resized/0004/8849/48849v1-max-250x250.png"],[[178,44],"assets/images/resized/0004/8849/48849v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://www.fiercebiotech.com/story/catabasis-nails-39m-series-diabetes-programs/2010-04-21","source_description":"Catabasis lands $39M Series A for diabetes programs","raised_amount":39000000,"raised_currency_code":"USD","funded_year":2010,"funded_month":4,"funded_day":21,"company":{"name":"Catabasis Pharmaceuticals","permalink":"catabasis-pharmaceuticals","image":{"available_sizes":[[[150,37],"assets/images/resized/0010/6512/106512v1-max-150x150.png"],[[250,62],"assets/images/resized/0010/6512/106512v1-max-250x250.png"],[[398,99],"assets/images/resized/0010/6512/106512v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"d","source_url":"http://www.fiercebiotech.com/story/inotek-gathers-18m-it-plots-phii-trials/2010-06-11?utm_medium=rss&utm_source=rss","source_description":"Inotek gathers $18M as it plots PhII trials  Read more: Inotek gathers $18M as it plots PhII trials","raised_amount":18000000,"raised_currency_code":"USD","funded_year":2010,"funded_month":6,"funded_day":11,"company":{"name":"Inotek Pharmaceuticals","permalink":"inotek-pharmaceuticals","image":{"available_sizes":[[[150,27],"assets/images/resized/0009/0460/90460v1-max-150x150.jpg"],[[185,34],"assets/images/resized/0009/0460/90460v1-max-250x250.jpg"],[[185,34],"assets/images/resized/0009/0460/90460v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.thefreelibrary.com/AVIDIA+ADVANCING+LEAD+PRODUCT+THROUGH+$28.5M+SERIES+B+ROUND.-a0132169338","source_description":"AVIDIA ADVANCING LEAD PRODUCT THROUGH $28.5M SERIES B ROUND.","raised_amount":28500000,"raised_currency_code":"USD","funded_year":2005,"funded_month":5,"funded_day":6,"company":{"name":"Avidia","permalink":"avidia","image":null}}},{"funding_round":{"round_code":"a","source_url":"http://finance.yahoo.com/news/Arginetix-and-Immune-Control-bw-1922954142.html?x=0&.v=1","source_description":"Arginetix and Immune Control Merge to Form Corridor Pharmaceuticals","raised_amount":15000000,"raised_currency_code":"USD","funded_year":2010,"funded_month":6,"funded_day":16,"company":{"name":"Corridor Pharmaceuticals","permalink":"corridor-pharmaceuticals","image":null}}},{"funding_round":{"round_code":"d","source_url":"http://www.ambitbio.com/news/press_061011.htm","source_description":"AMBIT BIOSCIENCES COMPLETES $30 MILLION SERIES D-2 FINANCING","raised_amount":30000000,"raised_currency_code":"USD","funded_year":2011,"funded_month":6,"funded_day":10,"company":{"name":"Ambit Biosciences","permalink":"ambit-biosciences","image":{"available_sizes":[[[95,108],"assets/images/resized/0013/8681/138681v1-max-150x150.png"],[[95,108],"assets/images/resized/0013/8681/138681v1-max-250x250.png"],[[95,108],"assets/images/resized/0013/8681/138681v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"a","source_url":"http://www.catabasispharma.com/pdfs/Catabasis_Final_Financing_PR_12.13.11.pdf","source_description":"Catabasis Pharmaceuticals Announces $8 Million Series A Extension Financing","raised_amount":8000000,"raised_currency_code":"USD","funded_year":2011,"funded_month":12,"funded_day":13,"company":{"name":"Catabasis Pharmaceuticals","permalink":"catabasis-pharmaceuticals","image":{"available_sizes":[[[150,37],"assets/images/resized/0010/6512/106512v1-max-150x150.png"],[[250,62],"assets/images/resized/0010/6512/106512v1-max-250x250.png"],[[398,99],"assets/images/resized/0010/6512/106512v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.marketwire.com/press-release/coferon-inc-announces-12-million-series-b-financing-1680034.htm","source_description":"Coferon, Inc. Announces $12 Million Series B Financing ","raised_amount":12000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":7,"funded_day":16,"company":{"name":"Coferon","permalink":"coferon","image":{"available_sizes":[[[150,41],"assets/images/resized/0020/1332/201332v1-max-150x150.jpg"],[[250,69],"assets/images/resized/0020/1332/201332v1-max-250x250.jpg"],[[313,87],"assets/images/resized/0020/1332/201332v1-max-450x450.jpg"]],"attribution":null}}}},{"funding_round":{"round_code":"unattributed","source_url":"http://finance.yahoo.com/news/ambit-biosciences-completes-50-million-130000590.html","source_description":"Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia","raised_amount":50000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":11,"funded_day":6,"company":{"name":"Ambit Biosciences","permalink":"ambit-biosciences","image":{"available_sizes":[[[95,108],"assets/images/resized/0013/8681/138681v1-max-150x150.png"],[[95,108],"assets/images/resized/0013/8681/138681v1-max-250x250.png"],[[95,108],"assets/images/resized/0013/8681/138681v1-max-450x450.png"]],"attribution":null}}}},{"funding_round":{"round_code":"b","source_url":"http://www.biospace.com/News/applied-genetic-technologies-corporation-lands-37/280113/Source=TopBreaking","source_description":"Applied Genetic Technologies Corporation Lands $37.5 Million in Venture Capital Funding","raised_amount":37500000,"raised_currency_code":"USD","funded_year":2012,"funded_month":11,"funded_day":19,"company":{"name":"Applied Genetics Technologies Corporation","permalink":"applied-genetics-technologies-corporation","image":{"available_sizes":[[[133,150],"assets/images/resized/0004/8997/48997v1-max-150x150.png"],[[150,169],"assets/images/resized/0004/8997/48997v1-max-250x250.png"],[[150,169],"assets/images/resized/0004/8997/48997v1-max-450x450.png"]],"attribution":null}}}}],"milestones":[],"providerships":[],"funds":[],"video_embeds":[],"external_links":[]}